What the Upwork Listing Likely Means for BIEL
1. Electrome is actively investing in ActiPatch as a commercial product
The Upwork job is not theoretical. It’s a real, funded project to redesign:
Retail packaging
Pharmacy countertop displays
Floor displays
Brand identity
Consumer‑facing materials
This is exactly what companies do when they are preparing a retail rollout or relaunch.
2. Electrome is treating ActiPatch as their product
The job description refers to:
“ELECTROME ACTIPATCH®”
“FDA‑cleared OTC medical device”
“Premium drug‑free pain therapy”
Electrome would not:
Hire designers
Build retail displays
Rebrand the product
Position it as a flagship offering
…unless they had commercial rights to ActiPatch.
This is indirect but meaningful evidence of a licensing or ownership arrangement.
3. This suggests BIEL has transferred or licensed rights
Because ActiPatch is historically a BIEL product, Electrome’s investment implies:
A licensing deal
A distribution agreement
A rights transfer
Or a deeper partnership
The exact structure is unknown, but the direction is clear:
Electrome is now the commercial driver of ActiPatch.
4. This is the first real sign of external capital and execution behind BIEL’s technology
For years, BIEL’s biggest weaknesses have been:
No marketing budget
No distribution muscle
No retail presence
No brand investment
Electrome’s actions directly address those gaps.
This is the first time in a long time that another company is visibly spending money to commercialize a BIEL‑linked product.
5. This could be the beginning of a broader commercialization push
The type of work Electrome is commissioning is not “testing the waters.”
It’s the kind of work companies do when they are preparing for:
Retail pharmacy placement
Big‑box store pitches
Online marketplace expansion
A brand relaunch
A multi‑SKU product line
This is a serious commercial step, not a casual experiment.
Bottom Line
BIEL’s ActiPatch technology is being actively commercialized by Electrome.
This is the strongest signal in years that:
Someone with resources is investing in the product
ActiPatch is being prepared for retail distribution
Electrome has some form of rights or partnership
BIEL’s technology is not dormant
This is directionally positive for BIEL,
but the scale, financial impact, and structure of the relationship remain unknown.
In a Best‑Case Scenario:
1. Electrome has secured commercial rights to ActiPatch
The packaging redesign project suggests Electrome is preparing ActiPatch for retail distribution, which would only happen if they have meaningful rights to the product.
This could mean:
A licensing agreement
A distribution agreement
A rights transfer
A co‑branding arrangement
2. Electrome invests in a full retail relaunch
The Upwork job includes:
Pharmacy countertop displays
Floor displays
Premium packaging
Brand identity system
This is exactly what companies do before pitching to:
CVS
Walgreens
Walmart
Amazon retail programs
If Electrome pushes ActiPatch into mainstream retail, BIEL’s technology finally gets the commercial muscle it never had.
3. Electrome funds clinical validation
If Electrome wants to scale ActiPatch, they may invest in:
Larger clinical trials
FDA 510(k) expansions
Insurance reimbursement pathways
This would be transformative for BIEL’s underlying tech.
4. BIEL receives royalties or milestone payments
If a licensing deal exists, BIEL could benefit through:
Upfront payments
Ongoing royalties
Minimum purchase commitments
This would give BIEL its first meaningful revenue stream in years.
1. Electrome is actively investing in ActiPatch as a commercial product
The Upwork job is not theoretical. It’s a real, funded project to redesign:
Retail packaging
Pharmacy countertop displays
Floor displays
Brand identity
Consumer‑facing materials
This is exactly what companies do when they are preparing a retail rollout or relaunch.
2. Electrome is treating ActiPatch as their product
The job description refers to:
“ELECTROME ACTIPATCH®”
“FDA‑cleared OTC medical device”
“Premium drug‑free pain therapy”
Electrome would not:
Hire designers
Build retail displays
Rebrand the product
Position it as a flagship offering
…unless they had commercial rights to ActiPatch.
This is indirect but meaningful evidence of a licensing or ownership arrangement.
3. This suggests BIEL has transferred or licensed rights
Because ActiPatch is historically a BIEL product, Electrome’s investment implies:
A licensing deal
A distribution agreement
A rights transfer
Or a deeper partnership
The exact structure is unknown, but the direction is clear:
Electrome is now the commercial driver of ActiPatch.
4. This is the first real sign of external capital and execution behind BIEL’s technology
For years, BIEL’s biggest weaknesses have been:
No marketing budget
No distribution muscle
No retail presence
No brand investment
Electrome’s actions directly address those gaps.
This is the first time in a long time that another company is visibly spending money to commercialize a BIEL‑linked product.
5. This could be the beginning of a broader commercialization push
The type of work Electrome is commissioning is not “testing the waters.”
It’s the kind of work companies do when they are preparing for:
Retail pharmacy placement
Big‑box store pitches
Online marketplace expansion
A brand relaunch
A multi‑SKU product line
This is a serious commercial step, not a casual experiment.
Bottom Line
BIEL’s ActiPatch technology is being actively commercialized by Electrome.
This is the strongest signal in years that:
Someone with resources is investing in the product
ActiPatch is being prepared for retail distribution
Electrome has some form of rights or partnership
BIEL’s technology is not dormant
This is directionally positive for BIEL,
but the scale, financial impact, and structure of the relationship remain unknown.
In a Best‑Case Scenario:
1. Electrome has secured commercial rights to ActiPatch
The packaging redesign project suggests Electrome is preparing ActiPatch for retail distribution, which would only happen if they have meaningful rights to the product.
This could mean:
A licensing agreement
A distribution agreement
A rights transfer
A co‑branding arrangement
2. Electrome invests in a full retail relaunch
The Upwork job includes:
Pharmacy countertop displays
Floor displays
Premium packaging
Brand identity system
This is exactly what companies do before pitching to:
CVS
Walgreens
Walmart
Amazon retail programs
If Electrome pushes ActiPatch into mainstream retail, BIEL’s technology finally gets the commercial muscle it never had.
3. Electrome funds clinical validation
If Electrome wants to scale ActiPatch, they may invest in:
Larger clinical trials
FDA 510(k) expansions
Insurance reimbursement pathways
This would be transformative for BIEL’s underlying tech.
4. BIEL receives royalties or milestone payments
If a licensing deal exists, BIEL could benefit through:
Upfront payments
Ongoing royalties
Minimum purchase commitments
This would give BIEL its first meaningful revenue stream in years.
